ストックスクリーナーアプリを入手
0.4129
3.20%
0.0128
プレマーケット:
.41
-0.0029
-0.70%
前日終値:
$0.4001
開ける：
$0.4
24時間の取引高:
545.89K
Relative Volume:
0.19
時価総額：
$3.45M
収益：
-
当期純損益:
$-15.52M
株価収益率:
-0.0222
EPS:
-18.58
ネットキャッシュフロー:
$-16.61M
1週間 パフォーマンス:
-12.28%
1か月 パフォーマンス:
+39.97%
6か月 パフォーマンス:
-75.42%
1年 パフォーマンス:
-96.68%
1日の値動き範囲:
$0.386
$0.42
1週間の範囲:
$0.386
$0.51
52週間の値動き範囲:
$0.281
$25.26
Revelation Biosciences Inc Stock (REVB) Company Profile
名前
Revelation Biosciences Inc
セクター
電話
650-800-3717
住所
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
REVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
0.4129 | 3.45M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revelation Biosciences Inc (REVB) 最新ニュース
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Marketscreener.com
Revelation Bio Launches Phase 1b Trial of Gemini for Advanced Chronic Kidney Disease Treatment - StockTitan
Florida Trader Among 4 Arrested for 7-Year-Long Insider Trading Scheme - NewsBreak
Revelation Biosciences (REVB) Price Target Increased by 242.79% to 40.04 - MSN
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Broker, Traders Charged With $1M Insider Trading Scheme - Law360
Personal Finance - Business Wire
Several More Companies Propose Move From Delaware To Nevada - JD Supra
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025 - Business Wire
Revelation Biosciences Plans Move to Nevada, Eyes $200K Annual Tax Savings - StockTitan
Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off - MSN
Nasdaq Grants Revelation Biosciences Inc. Continued Listing - BioSpace
Nasdaq grants Revelation Biosciences’ request for continued listing - MSN
Revelation Bio Secures Nasdaq Listing, Advances Kidney Disease Drug After FDA Green Light - StockTitan
Getty Images Rumored To Be In Merger Talks With Shutterstock: Retail Sees Potential Combination As ‘Win-Win’ Proposition - MSN
Stock market today: Neumora Therapeutics down by 81.14% while Rain Oncology surged by 676.86% in early trading - Business Upturn
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.97% - MSN
Revelation Biosciences stock hits 52-week low at $0.32 - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Revelation Biosciences files for secondary offering of common stock - MSN
Revelation Biosciences stock hits 52-week low at $0.42 - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.42 By Investing.com - Investing.com UK
Reviewing Emmaus Life Sciences (OTCMKTS:EMMA) and Revelation Biosciences (NASDAQ:REVB) - Defense World
Revelation Biosciences stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.7 - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Revelation Biosciences Secures $4M Through Warrant Exercise, Issues New Warrants - StockTitan
FDA approves Revelation Biosciences' drug trial for CKD By Investing.com - Investing.com Nigeria
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND - Marketscreener.com
FDA approves Revelation Biosciences' drug trial for CKD - Investing.com
Revelation Bio's Kidney Disease Drug Gemini Receives FDA IND Approval for Phase 1b Trial - StockTitan
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Warning: REVB is at high risk of performing badly - MSN
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - BioSpace
Revelation Bio Achieves Key Manufacturing Milestone for Kidney Disease Drug Trial | REVB Stock News - StockTitan
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
Allergic Rhinitis Treatment Market Size in the 7MM is expected to Grow by 2034 | DelveInsight - Barchart
REVB: Good Expense Control as Company Prepares for Trials - Research Tree
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket - Benzinga
REVB Results Set Stage for Future Growth - Yahoo Finance
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - sharewise
Revelation Biosciences Inc expected to post a loss of $2.29 a shareEarnings Preview - XM
Revelation Bio Q3 Loss Narrows to $2.2M, Secures $3.8M from Warrants Amid Cash Decline | REVB Stock News - StockTitan
Revelation Biosciences Inc (REVB) Quarterly 10-Q Report - Quartzy
Revelation Biosciences Inc (REVB) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):